Gut bacteria trial aims to slow ALS and dementia
NCT ID NCT06051123
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests whether a special probiotic supplement can change fat-related molecules in the blood of people with ALS and frontotemporal dementia (FTD). Researchers will compare those taking the probiotic to those taking a placebo over 24 weeks. The goal is to see if the probiotic affects disease progression and daily function. The trial involves 150 adults with mild to moderate symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS - AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Hospitalier de l'Université de Montréal
RECRUITINGMontreal, Quebec, H2X 0A9, Canada
-
Stan Cassidy Centre for Rehabilitation
RECRUITINGFredericton, New Brunswick, E3B 0C7, Canada
-
University of Saskatchewan, Clinical Trials Support Unit
RECRUITINGSaskatoon, Saskatchewan, S7N 0W8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood markers may unlock early ALS detection — a study puts them to the test
- Brain implant aims to give voice to those trapped in silence
- Nasal spray aims to tame brain inflammation in ALS
- Robotic arm could help people with paralysis regain independence at home
- Experimental cell therapy tested in 3 ALS patients
- Gene therapy injection hopes to slow ALS